CYMBALTA showed improvement over placebo on the primary endpoint [change from baseline to end-of-treatment on the Brief Pain Inventory (BPI) Modified Short Form: Adolescent Version 24-hour average pain severity rating] with a p-value of 0.052 from the pre-specified primary analysis, and p-values ranging from 0.011-0.020 from sensitivity analyses which assigned baseline values to missing assessments of some patients who did not complete the trial for various reasons
Oral semaglutide is typically seen as easier to use because it does not involve needles
and diabetic retinopathy complications in patients with pre-existing retinopathy
This article explains when early dosing is appropriate, what precautions to observe, and how to manage missed doses
These therapies target appetite, fat metabolism, and cellular energy, offering a science-backed edge over willpower alone
Under NICE TA875, semaglutide (Wegovy) treatment on the NHS is usually limited to 2 years within specialist weight management services